A study confirms the cardiovascular safety of different COVID-19 vaccine doses, showing reduced risks of common cardiovascular events among vaccinated adults in England.
Fianlimab by Regeneron Pharmaceuticals for Advanced Malignancy: Likelihood of Approval
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes